arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Autolus Therapeutics plc

AUTL Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$1.52
▼ -6.2% Today
as of Oct 23, 13:45 ET
Last 30 days -21.39% Sep 14 → Oct 23
$1.48 $1.63 $1.78 $1.92 $2.07 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$1.63
High
$1.64
Low
$1.53
Volume
$2M
Avg Vol
$2M
Mkt Cap
$492M
P/E (TTM)
—
Beta
—
52w High
$2.58
52w Low
$1.18
Div Yield
—
Shares Out
—

Recent Press Releases & News last 60 days · 4 items

Oct 5 · 15:00 Zacks
All You Need to Know About Autolus Therapeutics (AUTL) Rating Upgrade to Buy
Oct 5 · 12:30 PR GlobeNewswire
Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026
Sep 12 · 10:21 Insider Monkey
AUCATZYL Sales Are Exploding, But Autolus (AUTL) Still Isn’t In The Black
▸ Show all 4 press releases & news Free account →

AUTL earnings at a glance

The options market is pricing a move of about ±51.7% after the report, a range of roughly $0.73 to $2.31 from today's $1.52. Over its last 2 reports the stock rose the next day 1 time and fell 1, moving ±8.4% on average; after the most recent report on May 14, 2026 it moved -7.0%. That means options currently expect more movement than AUTL has typically delivered. AUTL beat the consensus EPS estimate in 2 of its last 4 reported quarters. Implied volatility is currently 253%. The share price of $1.52 sits in the middle of its 52-week range.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$1.18
$2.58
25% of range
Avg surprise (last 4)
-1.7%
Avg reaction (last 2)
+1.4%
50% positive
Latest IV / EM
253%
EM ±51.7% · $2 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.31$-0.27$-0.23$-0.19$-0.15 Actual $-0.23Actual $-0.26Actual $-0.26Actual $-0.24Actual $-0.22Actual $-0.31Actual $-0.26Est $-0.24Actual $-0.18Est $-0.24Actual $-0.30Est $-0.23Actual $-0.27Est $-0.29Actual $-0.15 MarJunSepMarJunSepMar/2025Jun/2025Sep/2025Mar/2026Jun
Revenue vs Net Income Revenue Net income
$-82M$-50M$-17M$15M$48M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.15 — — — — financials
Thu May 14, 2026Mar/2026 $-0.27 $-0.29 +6.9% -3.9% -7.0% earnings
Wed Nov 12, 2025Sep/2025 $-0.30 $-0.23 -30.4% — — earnings
Tue Aug 12, 2025Jun/2025 $-0.18 $-0.24 +25.0% — — earnings
Thu May 8, 2025Mar/2025 $-0.26 $-0.24 -8.3% — +9.8% earnings
Mon Sep 30, 2024Sep 2024 $-0.31 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.22 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.24 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.26 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.26 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.23 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$46M$26M—$21M$21M$9M—$0
Cost of revenue$20M$25M—$29M$24M$18M—$0
Gross profit————————
Operating income$-44M$-60M—$-72M$-61M$-65M—$-68M
Net income$-39M$-72M—$-79M$-48M$-70M—$-82M
EPS (diluted)$-0.15$-0.27—$-0.30$-0.18$-0.26—$-0.31

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$171M$131M$104M$86M$124M$96M$227M$657M
Inventory$33M$33M$33M$28M$24M$15M$4M—
Total current assets$336M$369M$436M$515M$574M$616M$661M$718M
Total assets$493M$527M$589M$662M$721M$746M$783M$827M
Long-term debt————————
Total liabilities$418M$418M$411M$396M$375M$375M$355M$351M
Total equity$75M$109M$178M$265M$346M$371M$427M$477M

Implied volatility — last 90 days

40%128%215%303%391% Jun 07 — IV 118% · EM ±16.3%Jun 08 — IV 233% · EM ±30.8%Jun 09 — IV 235% · EM ±29.4%Jun 11 — IV 174% · EM ±19.2%Jun 17 — IV 391% · EM ±16.3%Aug 03 — IV 47% · EM ±8.3%Aug 04 — IV 75% · EM ±12.9%Aug 05 — IV 47% · EM ±7.9%Aug 06 — IV 108% · EM ±17.5%Aug 07 — IV 106% · EM ±16.6%Aug 10 — IV 122% · EM ±16.9%Aug 12 — IV 113% · EM ±14.2%Aug 13 — IV 229% · EM ±27.0%Aug 14 — IV 189% · EM ±20.9%Aug 19 — IV 100% · EM ±5.9%Aug 20 — IV 144% · EM ±6.0%Aug 24 — IV 51% · EM ±10.7%Aug 25 — IV 50% · EM ±10.2%Aug 26 — IV 54% · EM ±10.7%Aug 27 — IV 54% · EM ±10.6%Aug 28 — IV 56% · EM ±10.7%Aug 31 — IV 48% · EM ±8.5%Sep 01 — IV 88% · EM ±15.2%Sep 02 — IV 201% · EM ±33.6%Sep 03 — IV 40% · EM ±6.5%Sep 04 — IV 129% · EM ±20.1%Sep 07 — IV 145% · EM ±20.1%Sep 08 — IV 153% · EM ±20.3%Sep 11 — IV 166% · EM ±18.3%Sep 14 — IV 219% · EM ±18.3%Sep 22 — IV 253% · EM ±51.7%

Sector peers

ALLO
Allogene Therapeutics, Inc.
$494M $1.23-7.8%
RGNX
REGENXBIO Inc.
$501M $6.80-5.1%
ENTX
Entera Bio Ltd.
$503M $2.88-5.7%
PROK
ProKidney Corp.
$517M $1.39-3.3%
TECX
Tectonic Therapeutic, Inc.
$444M $20.22-7.4%
EIKN
Eikon Therapeutics, Inc.
$564M $7.34-8.2%

AUTL earnings FAQ

What is AUTL's expected move for earnings?

Options currently price a move of about ±51.7%, or $0.79 per share either way from $1.52.

How does AUTL stock usually react to earnings?

Across the last 2 reports the average next-day move was ±8.4%, up 1 times and down 1 times.

What is AUTL's implied volatility?

AUTL's at-the-money implied volatility is about 253% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in